Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

Dysautonomia International - Great new research from Vanderbilt's

Potential role of Ivabradine in children with Long Covid and a

Cureus Choices and Challenges With Drug Therapy in Postural

Ivabradine - Could a Wonder Drug For POTS Work in ME/CFS

Karsten HEUSSER, Senior Physician Scientist

Physiological effects of ivabradine in heart failure and beyond

PDF) Age-dependent modulation of xenobiotic metabolism in primary

PDF) Formation of DNA adducts by methyleugenol in vitro, in mouse

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

Ivabradine in children with postural orthostatic tachycardia

PDF) Age-dependent modulation of xenobiotic metabolism in primary

Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine

Ivabradine effects on COVID-19-associated postural orthostatic

Randomized Trial of Ivabradine in Patients With Hyperadrenergic